Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- The Bronx and West Orange, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 36 people enrolled
- Started
- 1 Mar 2021
- Ended
- 24 Aug 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Romosozumab
- Denosumab
- Placebo
- Record updated
- 21 September 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Motor-complete or incomplete spinal cord injury (SCI) [all levels of lesion] classified using International Standards for Neurological Classification for Spinal Cord Injury (ISNCSCI) impairment scale] as ISNCSCI score A-C
- Duration of injury >3 years
- Males (18-65 years old) and females (premenopausal, between the ages of 18 and 55 years old)
- Areal bone mineral density (aBMD) at the distal femur <1.0 g/cm2 (determined at screening)
Who cannot take part
- History of prior bone disease (Paget's hyperparathyroidism, etc.)
- Men with known hypogonadism prior to spinal cord injury (SCI)
- Anabolic therapy longer than six months duration after spinal cord injury (SCI)
- Glucocorticoid administration longer than three months duration within the last year, and/or prescribed moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute spinal cord injury (SCI)
- Heterotopic ossification (HO) of the knee region (the distal femoral epiphysis is the primary endpoint); HO to any other boney region will not prevent study participation as long as contraindicated medications have not been prescribed)
- Active and/or history of coronary heart disease or stroke within the past year
- Endocrinopathies (hyperthyroidism, Cushing's disease or syndrome, etc.)
- Severe underlying chronic disease (e.g., COPD, end-stage heart disease, chronic renal failure)
- Current diagnosis of cancer or history of cancer
- Prescribed a bisphosphonate for HO, or prescribed any other agent to treat osteoporosis other than calcium and vitamin D
- Long-bone fracture of the leg within the past year
- Postmenopausal women
- Chronic alcohol abuse
- Hypocalcemia
- Pregnancy
- Electrical stimulation of the lower extremities
- Osteosarcoma
- Life expectancy less than 5 years
Where in United States
- James J. Peters VA Medical Center, Bronx, NYThe Bronx, United States
- Kessler Institute for RehabilitationWest Orange, United States
About the trial
What the trial wants to find out
Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD).
Read full original descriptionShow less
The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur <1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.
The 3 groups in the trial
- Romosozumab Treatment (baseline to month 11)Treatment being tested
Of the thirty-nine (39) individuals with chronic spinal cord injury (SCI) enrolled in this study, twenty-six (26) participants will be randomly selected to received romosozumab (210mg SQ) once a month for 12 months.
Treatment: Romosozumab
- Placebo (baseline to month 12)Placebo, for comparison
Of the thirty-nine (39) individuals with chronic SCI enrolled in this study, thirteen (13) participants will be randomly selected to received placebo injections (NS SQ) once a month for 12 months. They will follow study procedures identical to those performed by individuals in the treatment (romosozumab) group.
Treatment: Placebo
- Denosumab (month 12 to month 24)Existing treatment, for comparison
Both groups (treatment and placebo) will receive denosumab (60mg SQ) at months 12 and 18 for maintenance of or to further increase bone mineral density (BMD) at regions of interest (ROI).
Treatment: Denosumab
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 21 September 2026